LT3138575T - Liofilizuoto hgf paruošimas - Google Patents

Liofilizuoto hgf paruošimas

Info

Publication number
LT3138575T
LT3138575T LTEPPCT/JP2015/062523T LT15786509T LT3138575T LT 3138575 T LT3138575 T LT 3138575T LT 15786509 T LT15786509 T LT 15786509T LT 3138575 T LT3138575 T LT 3138575T
Authority
LT
Lithuania
Prior art keywords
freeze
hgf preparation
dried
dried hgf
preparation
Prior art date
Application number
LTEPPCT/JP2015/062523T
Other languages
English (en)
Inventor
Ryo OHORI
Kanta HORIE
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of LT3138575T publication Critical patent/LT3138575T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/JP2015/062523T 2014-04-28 2015-04-24 Liofilizuoto hgf paruošimas LT3138575T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014092888 2014-04-28
PCT/JP2015/062523 WO2015166885A1 (ja) 2014-04-28 2015-04-24 Hgf凍結乾燥製剤

Publications (1)

Publication Number Publication Date
LT3138575T true LT3138575T (lt) 2021-08-25

Family

ID=54358614

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/JP2015/062523T LT3138575T (lt) 2014-04-28 2015-04-24 Liofilizuoto hgf paruošimas

Country Status (15)

Country Link
US (1) US11547743B2 (lt)
EP (1) EP3138575B1 (lt)
JP (1) JP6568846B2 (lt)
KR (1) KR102291913B1 (lt)
CN (1) CN106456695B (lt)
AU (1) AU2015254307B2 (lt)
CA (1) CA2947396C (lt)
ES (1) ES2887079T3 (lt)
IL (1) IL248377B (lt)
LT (1) LT3138575T (lt)
MX (1) MX2016013667A (lt)
RU (1) RU2693472C2 (lt)
SG (2) SG10201809228RA (lt)
TW (2) TWI674902B (lt)
WO (1) WO2015166885A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー/エス 環部分にキャリア結合を有するcnpプロドラッグ
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
AU2017232582B2 (en) 2016-03-17 2022-07-14 Eisai R&D Management Co., Ltd. Method for producing activated hepatocyte growth factor (HGF)
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
AU2022272740A1 (en) * 2021-05-14 2023-11-02 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
JPWO2025013783A1 (lt) * 2023-07-07 2025-01-16

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
NZ232813A (en) 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JP2706704B2 (ja) 1989-06-05 1998-01-28 敏一 中村 組換ヒト肝実質細胞増殖因子
JP3036782B2 (ja) 1990-04-03 2000-04-24 三菱化学株式会社 ヒト肝実質細胞増殖因子の生産方法および該因子を産生する形質転換体
JP2577091B2 (ja) 1989-08-11 1997-01-29 三菱化学株式会社 肝実質細胞増殖因子及びそれをコードする遺伝子
JP2777678B2 (ja) 1990-06-11 1998-07-23 敏一 中村 組換ヒト肝実質細胞増殖因子及びその製造方法
JP3072628B2 (ja) 1990-11-19 2000-07-31 敏一 中村 ヒト肝実質細胞増殖因子をコードする染色体dna
JP3213985B2 (ja) 1991-10-18 2001-10-02 三菱化学株式会社 新規なタンパク質
JP3232714B2 (ja) 1992-11-20 2001-11-26 三菱化学株式会社 新規なタンパク質およびそれをコードする遺伝子
CA2102463A1 (en) 1992-11-05 1994-05-06 Mitsubishi Chemical Corporation Protein and gene encoding said protein
DK0686045T3 (da) * 1993-02-23 2001-03-05 Genentech Inc Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
JP2747979B2 (ja) 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Hgf凍結乾燥製剤
JP2859577B2 (ja) 1996-03-27 1999-02-17 三菱化学株式会社 肝実質細胞増殖因子
JP4463885B2 (ja) 1996-12-05 2010-05-19 敏一 中村 劇症肝炎疾患治療剤
JP2980888B2 (ja) 1998-07-09 1999-11-22 三菱化学株式会社 肝実質細胞増殖因子をコードする遺伝子
CA2375779A1 (en) 1999-05-31 2000-12-07 Mitsubishi Chemical Corporation Lyophilized hgf preparation
JP4090236B2 (ja) 2000-12-05 2008-05-28 三菱化学株式会社 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法
DE10204792A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
KR101222254B1 (ko) 2004-07-26 2013-01-16 제넨테크, 인크. 간세포 성장 인자 활성화를 조정하기 위한 조성물 및 방법
US7741096B2 (en) 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
JP5093783B2 (ja) 2006-04-20 2012-12-12 クリングルファーマ株式会社 Hgf前駆体蛋白質改変体及びその活性型蛋白質
WO2008078189A2 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Hgf製剤
RU2481824C2 (ru) * 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
CA2771817A1 (en) 2009-10-19 2011-04-28 Genentech, Inc. Modulators of hepatocyte growth factor activator
WO2011102845A1 (en) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
JP2012051822A (ja) 2010-08-31 2012-03-15 Institute Of Physical & Chemical Research 肺癌診断用ポリペプチド、肺癌の検出方法、および治療効果の評価方法
WO2012144535A1 (ja) 2011-04-18 2012-10-26 国立大学法人京都大学 急性肝不全抑制剤及びその薬効評価法
US20130071931A1 (en) 2011-08-02 2013-03-21 National Cancer Center Process for hepatic differentiation from induced hepatic stem cells, and induced hepatic progenitor cells differentiated thereby
JP6387009B2 (ja) 2012-10-20 2018-09-05 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 癌細胞トラップ
RU2506946C1 (ru) 2012-11-28 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Технология лиофилизации обогащенной тромбоцитами плазмы с сохранением жизнеспособности факторов tgf pdgf vegf
EP3431992A4 (en) 2016-03-18 2019-10-23 Eisai R&D Management Co., Ltd. PD MARKERS OF THE HEPATOCYTE GROWTH FACTOR (HGF)
CN106175986B (zh) 2016-07-26 2017-12-01 复旦大学附属中山医院 一种瓣膜夹合器

Also Published As

Publication number Publication date
CA2947396A1 (en) 2015-11-05
CN106456695A (zh) 2017-02-22
RU2016146121A (ru) 2018-05-28
TWI674902B (zh) 2019-10-21
RU2016146121A3 (lt) 2018-11-28
RU2693472C2 (ru) 2019-07-03
ES2887079T3 (es) 2021-12-21
TW202017588A (zh) 2020-05-16
US20170189487A1 (en) 2017-07-06
MX2016013667A (es) 2017-01-23
AU2015254307A2 (en) 2016-11-24
TW201601747A (zh) 2016-01-16
IL248377B (en) 2020-04-30
EP3138575A4 (en) 2018-01-24
WO2015166885A1 (ja) 2015-11-05
JP6568846B2 (ja) 2019-08-28
JPWO2015166885A1 (ja) 2017-04-20
CN106456695B (zh) 2019-11-12
SG11201608583YA (en) 2016-11-29
AU2015254307A1 (en) 2016-11-10
SG10201809228RA (en) 2018-11-29
TWI728409B (zh) 2021-05-21
BR112016025051A2 (pt) 2018-02-20
RU2019119586A3 (lt) 2022-01-25
AU2015254307B2 (en) 2019-11-07
IL248377A0 (en) 2016-11-30
CA2947396C (en) 2021-10-19
EP3138575A1 (en) 2017-03-08
KR20160146736A (ko) 2016-12-21
EP3138575B1 (en) 2021-07-14
KR102291913B1 (ko) 2021-08-23
US11547743B2 (en) 2023-01-10
RU2019119586A (ru) 2019-07-26

Similar Documents

Publication Publication Date Title
ES2648672T5 (en) Improved hvt-vectored nd-ibd vaccine
GB201518684D0 (en) Vaccine
IL254132A0 (en) Solid preparation
IL281197B (en) Formulations of factor ix that have been lyophilized
AU358659S (en) Blender
SG11201702298VA (en) Pharmaceutical preparation
ZA201708081B (en) Preparation comprising arabinoxylo-oligosaccharides
GB201513434D0 (en) Blower
EP3138575A4 (en) Freeze-dried hgf preparation
GB201501938D0 (en) Probiotic preparation
AU361694S (en) Blender
IL257884A (en) Freeze-dried alginic acid preparation
GB201522132D0 (en) Vaccine
GB201800538D0 (en) Games
PL3383937T3 (pl) Ulepszone wytwarzanie polimeru
GB201507279D0 (en) Odontalgic preparation
GB201410184D0 (en) Odontalgic preparation
GB201521608D0 (en) Vaccine composition
PL3023093T3 (pl) Preparat leczniczy oparty na diosmektycie
CN303072196S (zh) 车灯(21)
AU361693S (en) Blender
PH32015000049S1 (en) Blender
GB201411371D0 (en) Immunogenic composition
GB201411306D0 (en) Immunogenic composition
AU358660S (en) Blender